Preferred Label : Chimeric Antigen Receptor Therapy;
Origin ID : M000639995;
Related record
https://www.has-sante.fr/jcms/p_3639814/fr/carvykti-ciltacabtagene-autoleucel-myelome-multiple
2025
false
false
false
France
economic evaluation
insurance, health, reimbursement
treatment outcome
Refractory Multiple Myeloma
adult
Recurrent Multiple Myeloma
Ciltacabtagene Autoleucel
ciltacabtagene autoleucel
Receptors, Chimeric Antigen
immunotherapy, adoptive
b-cell maturation antigen
Chimeric Antigen Receptor Therapy
infusions, intravenous
disease progression
survival analysis
evaluation of the transparency committee
multiple myeloma
---
https://ansm.sante.fr/informations-de-securite/abecma-breyanzi-carvykti-kymriah-tecartus-et-yescarta-therapies-cellulaires-car-t-dirigees-contre-les-antigenes-cd19-ou-bcma-risque-de-tumeur-maligne-secondaire-issue-de-lymphocytes-t
2024
false
false
false
France
French
pharmacovigilance note
Secondary Malignant Neoplasm
Anti-CD19 CAR T Cells Preparation
Anti-BCMA CAR T Cells Preparation
Chimeric Antigen Receptor Therapy
lymphoma, T-Cell
continuity of patient care
hematologic neoplasms
leukemia, t-cell
Antineoplastic cell and gene therapy
---
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-janvier-2024-8-11-janvier
2024
false
false
false
France
French
risk management
valproic acid
Male
Neurodevelopmental Disorders
Chimeric antigen receptor T-cell therapy
genetic therapy
Secondary Carcinoma
Chimeric Antigen Receptor Therapy
immunotherapy, adoptive
pharmacovigilance note
---
https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-juin-2024-10-13-juin
2024
false
false
false
France
French
pharmacovigilance note
risk assessment
risk
dipyrone
agranulocytosis
gene therapy
Chimeric Antigen Receptor T-cells
Antineoplastic Agents, Immunological
Therapy-Associated cancer
Chimeric Antigen Receptor Therapy
---
